CA2723798A1 - Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds - Google Patents
Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds Download PDFInfo
- Publication number
- CA2723798A1 CA2723798A1 CA2723798A CA2723798A CA2723798A1 CA 2723798 A1 CA2723798 A1 CA 2723798A1 CA 2723798 A CA2723798 A CA 2723798A CA 2723798 A CA2723798 A CA 2723798A CA 2723798 A1 CA2723798 A1 CA 2723798A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- hydroxyalkyl
- hydrocarbyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 239000003814 drug Substances 0.000 claims abstract description 6
- -1 halohydrocarbyl Chemical group 0.000 claims description 149
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 69
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 68
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 63
- 125000003118 aryl group Chemical group 0.000 claims description 62
- 150000002431 hydrogen Chemical class 0.000 claims description 55
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 54
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 51
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 51
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 51
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 50
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 50
- 125000003282 alkyl amino group Chemical group 0.000 claims description 47
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 42
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 23
- 125000001475 halogen functional group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 230000036407 pain Effects 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 150000001412 amines Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010061323 Optic neuropathy Diseases 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- XOCUXOWLYLLJLV-UHFFFAOYSA-N [O].[S] Chemical compound [O].[S] XOCUXOWLYLLJLV-UHFFFAOYSA-N 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 201000010183 Papilledema Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038886 Retinal oedema Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000006218 bradycardia Diseases 0.000 claims description 2
- 230000036471 bradycardia Effects 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 201000011195 retinal edema Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 19
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 49
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 38
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 37
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- 239000000543 intermediate Substances 0.000 description 28
- 125000005843 halogen group Chemical group 0.000 description 27
- 239000000460 chlorine Substances 0.000 description 26
- 229910052801 chlorine Inorganic materials 0.000 description 24
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 101150041968 CDC13 gene Proteins 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 229910052786 argon Inorganic materials 0.000 description 19
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000000524 functional group Chemical group 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000010626 work up procedure Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 6
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 150000003408 sphingolipids Chemical class 0.000 description 6
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 5
- KNQQKKJIUATUAK-UHFFFAOYSA-N ac1mefeo Chemical compound C1=2C3=CC(N)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 KNQQKKJIUATUAK-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000008098 formaldehyde solution Substances 0.000 description 5
- 239000008241 heterogeneous mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000004962 sulfoxyl group Chemical group 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- KRJBINYTHHTEJJ-WMPKNSHKSA-N (4S,10R)-4,10-dimethyl-4,10-diphenyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-amine Chemical compound C1([C@@]2(CCN3CC[C@](C=4C=C(N)C=C2C3=4)(C)C=2C=CC=CC=2)C)=CC=CC=C1 KRJBINYTHHTEJJ-WMPKNSHKSA-N 0.000 description 3
- ARFDAFPFUOXGEM-UHFFFAOYSA-N 1,7-dimethyl-9-nitro-1,7-diphenyl-2,3,6,7-tetrahydro-1h,5h-pyrido[3,2,1-ij]quinoline Chemical compound C=12C3=CC([N+]([O-])=O)=CC=1C(C)(C=1C=CC=CC=1)CCN2CCC3(C)C1=CC=CC=C1 ARFDAFPFUOXGEM-UHFFFAOYSA-N 0.000 description 3
- FJVIEPFUBPLIME-UHFFFAOYSA-N 1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-propylthiourea Chemical compound C1=2C3=CC(NC(=S)NCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 FJVIEPFUBPLIME-UHFFFAOYSA-N 0.000 description 3
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- HNLYBCHBNFOUKY-UHFFFAOYSA-N 1-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea Chemical compound C1=2C3=CC(NC(=O)NCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 HNLYBCHBNFOUKY-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 2
- FPIWFRIRLLDRMG-UHFFFAOYSA-N 2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)acetic acid Chemical compound C1=2C3=CC(CC(=O)O)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 FPIWFRIRLLDRMG-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 2
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000006423 bromocyclopropyl group Chemical group 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000006425 chlorocyclopropyl group Chemical group 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- QHQVUUZYTYDPTG-UHFFFAOYSA-N ethyl 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylate Chemical compound C1=2C3=CC(C(=O)OCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 QHQVUUZYTYDPTG-UHFFFAOYSA-N 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000006428 iodocyclopropyl group Chemical group 0.000 description 2
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- RMYSPERASWYIIN-HNRBIFIRSA-N methyl N-[(4S,10R)-4,10-dimethyl-4,10-diphenyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-yl]carbamate Chemical compound C1([C@@]2(C)CCN3C4=C2C=C(C=C4[C@](C)(C=2C=CC=CC=2)CC3)NC(=O)OC)=CC=CC=C1 RMYSPERASWYIIN-HNRBIFIRSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003410 sphingosines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZPLLXGJVIAAKHK-UHFFFAOYSA-N 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxylic acid Chemical compound C1=2C3=CC(C(=O)O)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 ZPLLXGJVIAAKHK-UHFFFAOYSA-N 0.000 description 1
- TZFCMXCHVILLLB-VMPREFPWSA-N 1-((1s,7s)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-3-ethylurea Chemical compound C1([C@]2(C)CCN3C4=C2C=C(C=C4[C@](C)(C=2C=CC=CC=2)CC3)NC(=O)NCC)=CC=CC=C1 TZFCMXCHVILLLB-VMPREFPWSA-N 0.000 description 1
- KKASGUHLXWAKEZ-UHFFFAOYSA-N 1-isothiocyanatopropane Chemical compound CCCN=C=S KKASGUHLXWAKEZ-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- OKBPVNFRQFNRPH-UHFFFAOYSA-N 3-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)-1,1-dimethylurea Chemical compound C1=2C3=CC(NC(=O)N(C)C)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 OKBPVNFRQFNRPH-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CECDCGGZCGCYJS-UHFFFAOYSA-N C1=2C3=CC(C(=O)NCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(C(=O)NCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 CECDCGGZCGCYJS-UHFFFAOYSA-N 0.000 description 1
- MDISYLVLHLEKLT-UHFFFAOYSA-N C1=2C3=CC(C(=O)NCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(C(=O)NCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 MDISYLVLHLEKLT-UHFFFAOYSA-N 0.000 description 1
- GJGQNIOMEQDQTF-UHFFFAOYSA-N C1=2C3=CC(C(=O)NCCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(C(=O)NCCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 GJGQNIOMEQDQTF-UHFFFAOYSA-N 0.000 description 1
- RQLOLMUMRHQVTC-UHFFFAOYSA-N C1=2C3=CC(C(=O)NCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(C(=O)NCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 RQLOLMUMRHQVTC-UHFFFAOYSA-N 0.000 description 1
- ZFHGFWNZYOIUCX-UHFFFAOYSA-N C1=2C3=CC(C(=O)NCCO)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(C(=O)NCCO)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 ZFHGFWNZYOIUCX-UHFFFAOYSA-N 0.000 description 1
- MUJPNMLJBOBZQC-UHFFFAOYSA-N C1=2C3=CC(NC(=O)NC(C)(C)C)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)NC(C)(C)C)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 MUJPNMLJBOBZQC-UHFFFAOYSA-N 0.000 description 1
- XPMWERALDTXZHD-UHFFFAOYSA-N C1=2C3=CC(NC(=O)NCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)NCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 XPMWERALDTXZHD-UHFFFAOYSA-N 0.000 description 1
- BKSNPHZBGQTVRX-UHFFFAOYSA-N C1=2C3=CC(NC(=O)NCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)NCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 BKSNPHZBGQTVRX-UHFFFAOYSA-N 0.000 description 1
- PSSCKYRWUICTSX-UHFFFAOYSA-N C1=2C3=CC(NC(=O)NCCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)NCCCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 PSSCKYRWUICTSX-UHFFFAOYSA-N 0.000 description 1
- VWMPDGPOBCZOPZ-UHFFFAOYSA-N C1=2C3=CC(NC(=O)NCCCl)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)NCCCl)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 VWMPDGPOBCZOPZ-UHFFFAOYSA-N 0.000 description 1
- XJYQELGJWWANJY-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(NC(=O)OC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 XJYQELGJWWANJY-UHFFFAOYSA-N 0.000 description 1
- CRNMGUCGHKGQEI-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCC(C)C)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)OCC(C)C)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 CRNMGUCGHKGQEI-UHFFFAOYSA-N 0.000 description 1
- UZIUHKRFNFRKKB-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(NC(=O)OCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 UZIUHKRFNFRKKB-UHFFFAOYSA-N 0.000 description 1
- KAYYNQJAQBCHSC-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)OCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 KAYYNQJAQBCHSC-UHFFFAOYSA-N 0.000 description 1
- ILGIADZNXMTRDJ-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(NC(=O)OCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 ILGIADZNXMTRDJ-UHFFFAOYSA-N 0.000 description 1
- YUKPWVFOPHKFQJ-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)OCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 YUKPWVFOPHKFQJ-UHFFFAOYSA-N 0.000 description 1
- HLOIODRGAIWLCL-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 Chemical compound C1=2C3=CC(NC(=O)OCCCC)=CC=2C(C=2C=C(F)C=CC=2)CCN1CCC3C1=CC=CC(F)=C1 HLOIODRGAIWLCL-UHFFFAOYSA-N 0.000 description 1
- MYWNOXWBPOVRGX-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)OCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 MYWNOXWBPOVRGX-UHFFFAOYSA-N 0.000 description 1
- RPSNTZUZFZTWPD-UHFFFAOYSA-N C1=2C3=CC(NC(=O)OCCF)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 Chemical compound C1=2C3=CC(NC(=O)OCCF)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 RPSNTZUZFZTWPD-UHFFFAOYSA-N 0.000 description 1
- LQDMLSGXKITHPS-UHFFFAOYSA-N C=1C(=C23)C(C=4C=CC=CC=4)CCN3CCC(C=3C=CC=CC=3)C2=CC=1NC(=O)NCC=1C=COC=1 Chemical compound C=1C(=C23)C(C=4C=CC=CC=4)CCN3CCC(C=3C=CC=CC=3)C2=CC=1NC(=O)NCC=1C=COC=1 LQDMLSGXKITHPS-UHFFFAOYSA-N 0.000 description 1
- AODZWWZMUKSGMZ-UHFFFAOYSA-N C=1C=CC=CC=1COC(=O)NC(C=C1C=23)=CC=2C(C=2C=CC=CC=2)CCN3CCC1C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1COC(=O)NC(C=C1C=23)=CC=2C(C=2C=CC=CC=2)CCN3CCC1C1=CC=CC=C1 AODZWWZMUKSGMZ-UHFFFAOYSA-N 0.000 description 1
- BBCCKXBVRDVXOK-UHFFFAOYSA-N C=1C=CC=CC=1OC(=O)NC(C=C1C=23)=CC=2C(C=2C=CC=CC=2)CCN3CCC1C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1OC(=O)NC(C=C1C=23)=CC=2C(C=2C=CC=CC=2)CCN3CCC1C1=CC=CC=C1 BBCCKXBVRDVXOK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000547 effect on apoptosis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- DZFWNZJKBJOGFQ-UHFFFAOYSA-N julolidine Chemical compound C1CCC2=CC=CC3=C2N1CCC3 DZFWNZJKBJOGFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- RMYSPERASWYIIN-NSOVKSMOSA-N methyl (1s,7s)-1,7-dimethyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate Chemical compound C1([C@]2(C)CCN3C4=C2C=C(C=C4[C@](C)(C=2C=CC=CC=2)CC3)NC(=O)OC)=CC=CC=C1 RMYSPERASWYIIN-NSOVKSMOSA-N 0.000 description 1
- ZTLSFLYGVOUTFI-UHFFFAOYSA-N methyl 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-ylcarbamate Chemical compound C1=2C3=CC(NC(=O)OC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 ZTLSFLYGVOUTFI-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
- SXGURHSLXPDJBC-UHFFFAOYSA-N n-(5-aminopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC=C(N)C=N1 SXGURHSLXPDJBC-UHFFFAOYSA-N 0.000 description 1
- CANLDFLYBBBTKC-UHFFFAOYSA-N n-butyl-1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carboxamide Chemical compound C1=2C3=CC(C(=O)NCCCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 CANLDFLYBBBTKC-UHFFFAOYSA-N 0.000 description 1
- JRBGYUUXXDVJMT-UHFFFAOYSA-N n-ethyl-2-(1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)acetamide Chemical compound C1=2C3=CC(CC(=O)NCC)=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 JRBGYUUXXDVJMT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- JFLJVMDQEKKXKN-UHFFFAOYSA-N st019647 Chemical compound C1=2C3=CC([N+](=O)[O-])=CC=2C(C=2C=CC=CC=2)CCN1CCC3C1=CC=CC=C1 JFLJVMDQEKKXKN-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5153308P | 2008-05-08 | 2008-05-08 | |
| US61/051,533 | 2008-05-08 | ||
| US12/433,978 | 2009-05-01 | ||
| US12/433,978 US20090281322A1 (en) | 2008-05-08 | 2009-05-01 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
| PCT/US2009/043149 WO2009137681A1 (en) | 2008-05-08 | 2009-05-07 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2723798A1 true CA2723798A1 (en) | 2009-11-12 |
Family
ID=40863539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2723798A Abandoned CA2723798A1 (en) | 2008-05-08 | 2009-05-07 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090281322A1 (OSRAM) |
| EP (1) | EP2294069B1 (OSRAM) |
| JP (1) | JP5432246B2 (OSRAM) |
| CN (1) | CN102089306A (OSRAM) |
| AU (1) | AU2009244199B2 (OSRAM) |
| BR (1) | BRPI0912534A2 (OSRAM) |
| CA (1) | CA2723798A1 (OSRAM) |
| IL (1) | IL209200A0 (OSRAM) |
| RU (1) | RU2010149312A (OSRAM) |
| WO (1) | WO2009137681A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013024657A2 (pt) * | 2011-03-25 | 2016-12-20 | Allergan Inc | antagonistas da s1p como hipotensivos oculares adjuntos |
| KR101691954B1 (ko) | 2016-04-26 | 2017-01-02 | 고려대학교 산학협력단 | 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물 |
| CN107369775B (zh) * | 2017-07-13 | 2018-12-25 | 长春海谱润斯科技有限公司 | 一种有机电致发光材料及其有机发光器件 |
| CN107492597B (zh) * | 2017-08-10 | 2018-11-27 | 长春海谱润斯科技有限公司 | 一种顶发射有机发光器件 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005519915A (ja) * | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| AU2003263413A1 (en) * | 2002-09-17 | 2004-04-08 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| US20040131648A1 (en) * | 2002-10-24 | 2004-07-08 | The Procter & Gamble Company | Nuclear hormone receptor compounds, products and methods employing same |
| US20040167185A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-3 receptor |
| EP2298770A1 (en) * | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| WO2007112322A2 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
-
2009
- 2009-05-01 US US12/433,978 patent/US20090281322A1/en not_active Abandoned
- 2009-05-07 CN CN2009801266353A patent/CN102089306A/zh active Pending
- 2009-05-07 BR BRPI0912534A patent/BRPI0912534A2/pt not_active IP Right Cessation
- 2009-05-07 WO PCT/US2009/043149 patent/WO2009137681A1/en not_active Ceased
- 2009-05-07 AU AU2009244199A patent/AU2009244199B2/en not_active Ceased
- 2009-05-07 EP EP09743667.9A patent/EP2294069B1/en not_active Not-in-force
- 2009-05-07 RU RU2010149312/04A patent/RU2010149312A/ru not_active Application Discontinuation
- 2009-05-07 JP JP2011508667A patent/JP5432246B2/ja not_active Expired - Fee Related
- 2009-05-07 CA CA2723798A patent/CA2723798A1/en not_active Abandoned
-
2010
- 2010-11-08 IL IL209200A patent/IL209200A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0912534A2 (pt) | 2015-10-13 |
| JP2011527286A (ja) | 2011-10-27 |
| EP2294069A1 (en) | 2011-03-16 |
| JP5432246B2 (ja) | 2014-03-05 |
| CN102089306A (zh) | 2011-06-08 |
| IL209200A0 (en) | 2011-01-31 |
| EP2294069B1 (en) | 2015-09-02 |
| AU2009244199B2 (en) | 2013-09-19 |
| AU2009244199A1 (en) | 2011-10-06 |
| US20090281322A1 (en) | 2009-11-12 |
| WO2009137681A1 (en) | 2009-11-12 |
| RU2010149312A (ru) | 2012-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5338849A (en) | Azaindoles, preparation processes and medicinal products containing them | |
| CA3026024C (en) | Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated with these | |
| MX2015005562A (es) | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa. | |
| CA2860933C (en) | Fused pyrroledicarboxamides and their use as pharmaceuticals | |
| CA3221788A1 (en) | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels | |
| AU2004255191A1 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| KR20050069977A (ko) | 디히드로피라졸로피리딘 화합물 | |
| AU2005303904A1 (en) | Azaindole carboxamides | |
| TW202216677A (zh) | 作為ａｌｋ５抑制劑之嗒基胺基衍生物 | |
| JP2009507795A (ja) | 化合物 | |
| TW202328102A (zh) | 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物 | |
| AU2009244199B2 (en) | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | |
| US6977262B2 (en) | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | |
| KR0163413B1 (ko) | 신경이완성 퍼하이드로-1H-피리도[1,2-a] 피라진 | |
| KR20030076650A (ko) | 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도 | |
| JP2025523939A (ja) | 新規のナフチルおよびイソキノリンスルホンアミド誘導体 | |
| US8431702B2 (en) | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | |
| IL282142B1 (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| JP2025525078A (ja) | 新規なスルホンアミドならびに神経保護剤および／または神経修復剤としてのそれらの使用 | |
| FR2906251A1 (fr) | Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique | |
| MX2015005560A (es) | Derivados de imidazopiridina. | |
| CN121735945A (zh) | 杂环化合物、其药物组合物及其用途 | |
| US10081633B2 (en) | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | |
| US20200123141A1 (en) | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | |
| TW202448900A (zh) | Irak4降解劑及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140401 |
|
| FZDE | Discontinued |
Effective date: 20160509 |